Aprepitant - CAS 170729-80-3
Catalog number:
170729-80-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Neurokinin Receptor
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
white solid powder
Synonyms:
Emend, L-754030; MK-0869; ONO-7436.
MSDS:
Inquire
1.Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process.
Kalvakuntla S1, Deshpande M2, Attari Z1, Kunnatur B K1. Adv Pharm Bull. 2016 Mar;6(1):83-90. doi: 10.15171/apb.2016.013. Epub 2016 Mar 17.
PURPOSE: Nanosuspension in drug delivery is known to improve solubility, dissolution and eventually bioavailability of the drugs. The purpose of the study was to compare particle size of nanosuspensions prepared by the first generation approach and H96 approach and to evaluate the effectiveness of H96 approach.
2.Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T1, Kyomori C2, Mizukami T1, Taniyama T1, Izawa N1, Horie Y1, Hirakawa M1, Ogura T1, Nakajima TE1, Tsugawa K3, Boku N1. Mol Clin Oncol. 2016 Apr;4(4):603-606. Epub 2016 Feb 5.
The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.
3.A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
Aridome K1, Mori SI2, Baba K2, Yanagi M2, Hamanoue M3, Miyazono F4, Tokuda K5, Imamura H6, Ogura Y7, Kaneko K8, Kijima F9, Maemura K2, Ishigami S2, Natsugoe S2. Mol Clin Oncol. 2016 Mar;4(3):393-398. Epub 2015 Dec 31.
The present study aimed to study the efficacy of aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC) for colorectal cancer (CRC), and comprised a multicenter, phase II, open-label, randomized, parallel comparative study conducted as part of the Kagoshima aprepitant study for colon cancer in Japan. Patients with advanced or recurrent CRC were treated with standard MEC regimens (FOLFOX, XELOX or FOLFIRI) and received either standard chemotherapy [5-hydroxytryptamine-3 receptor antagonist (5-HT3RA) + dexamethasone] or aprepitant regimen chemotherapy (5-HT3 RA + reduced-dose dexamethasone + aprepitant). The primary endpoint of the present study was the proportion of patients who achieved a complete response (CR) during the overall, acute, and delayed phases of the first planned chemotherapy cycle. Secondary endpoints were complete protection, the proportions of patients without emetic episodes or nausea, patients with no more than moderate nausea during the overall, acute and delayed phases, and the time to treatment failure.
4.Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Yang CK1, Wu CE1, Liaw CC2. Biomed J. 2016 Feb;39(1):60-6. doi: 10.1016/j.bj.2015.08.006. Epub 2016 Mar 29.
BACKGROUND: The purpose of this study was to evaluate the efficacy of combined treatment with the long-acting 5-hydroxytryptamine receptor-3 antagonist, palonosetron, the neurokinin-1 receptor antagonist, oral aprepitant, and dexamethasone as primary antiemetic prophylaxis for cancer patients receiving highly emetogenic cisplatin-based chemotherapy.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Neurokinin Receptor Products


CAS 914462-92-3 Rolapitant HCl hydrate

Rolapitant HCl hydrate
(CAS: 914462-92-3)

Rolapitant, also known as SCH-619734, is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist with potential antiemetic activity. Unl...

CAS 63968-82-1 Kassinin

Kassinin
(CAS: 63968-82-1)

Kassinin, a tachykinin peptide derived from the Kassina frog, is secreted as a defense response, and is involved in neuropeptide signalling and shows selectivit...

Talnetant hydrochloride
(CAS: 204519-66-4)

Talnetant is the hydrochloride salt of Talnetant. Talnetant, also called as SB 223412, is a selective, competitive, nonpeptide NK3 receptor antagonist and is in...

CAS 170729-80-3 Aprepitant

Aprepitant
(CAS: 170729-80-3)

CAS 33507-63-0 Substance P

Substance P
(CAS: 33507-63-0)

Substance P, a neuropeptide, is a sensory neuropeptide and inflammatory mediator. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor...

CAS 290297-26-6 Netupitant

Netupitant
(CAS: 290297-26-6)

Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity o...

CAS 148700-85-0 L-733,060

L-733,060
(CAS: 148700-85-0)

L-733,061, a phenylpiperidine derivative, has been found to be a NK1 receptor antagonist that could probably be antidepressant/ anxiolytic agent and also show a...

CAS 172673-20-0 Fosaprepitant dimeglumine

Fosaprepitant dimeglumine
(CAS: 172673-20-0)

CAS 148687-76-7 L-733,060 hydrochloride

L-733,060 hydrochloride
(CAS: 148687-76-7)

The hydrochloride salt form of L-733,061, a phenylpiperidine derivative, has been found to be a NK1 receptor antagonist that could probably be antidepressant/ a...

CAS 214487-46-4 MEN11467

MEN11467
(CAS: 214487-46-4)

MEN11467, a pseudopeptide,is a new tachykinin NK1 receptor antagonist which potently antagonizes both tachykinin and antigen-mediated inflammatory responses of ...

CAS 86933-75-7 Neurokinin B

Neurokinin B
(CAS: 86933-75-7)

Neurokinin B, one of the tachykinin family of peptides, binds a family of GPCRs—including neurokinin receptor 1 (NK1R), NK2R, and NK3R to mediate their biologic...

CAS 147116-67-4 Maropitant

Maropitant
(CAS: 147116-67-4)

CAS 122063-01-8 [bAla8]-Neurokinin A(4-10)

[bAla8]-Neurokinin A(4-10)
(CAS: 122063-01-8)

An agonist of neurokinin 2 (NK2) receptor

CAS 110880-55-2 [Sar9,Met(O2)11]-Substance P

[Sar9,Met(O2)11]-Substance P
(CAS: 110880-55-2)

A selective agonist of tachykinin NK1 receptor

CAS 2507-24-6 Physalaemin

Physalaemin
(CAS: 2507-24-6)

Physalaemin, a non-mammalian tachykinin originally isolated from the Physalaemus frog, binds selectively to neurokinin-1 (NK1) receptor with high affinity.

CAS 97559-35-8 Neurokinin A(4-10)

Neurokinin A(4-10)
(CAS: 97559-35-8)

Neurokinin A (4-10), an endogenous neuromodulatory peptide formerly known as substance K, is atachykinin NK2 receptor agonist.

CAS 137593-52-3 GR 64349

GR 64349
(CAS: 137593-52-3)

GR 64349 is a potent and selective agonist of tachykinin NK2 receptor (EC50 = 3.7 nM in rat colon).

CAS 86933-74-6 Neurokinin A

Neurokinin A
(CAS: 86933-74-6)

Neurokinin A is a member of the endogenous tachykinin agonist with preference for the NK-2R (NK-2 receptor).

Chemical Structure

CAS 170729-80-3 Aprepitant

Quick Inquiry

Verification code

Featured Items